Robert T. Heelan

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Vincent A. Miller, Mark G. Kris, Neelam Shah et al. · Journal of Clinical Oncology · 2004 · 744 citations

Screening for Early Lung Cancer

Myron R. Melamed, Betty J. Flehinger, Muhammad Zaman et al. · CHEST Journal · 1984 · 538 citations

Early Lung Cancer, Cancer Detection, Cancer Screening +7

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen et al. · Investigational New Drugs · 1994 · 440 citations

Oncology, Phase Ii Trial, Pancreatic Cancer +5